Senti Biosciences, Inc. (SNTI)

Market Cap	80.59M
Revenue (ttm)	n/a
Net Income (ttm)	-57.31M
Shares Out	26.08M
EPS (ttm)	-9.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,535
Open	3.180
Previous Close	3.090
Day's Range	3.100 - 3.209
52-Week Range	1.520 - 16.940
Beta	2.32
Analysts	Strong Buy
Price Target	12.00 (+288.35%)
Earnings Date	May 6, 2025

About SNTI

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood can...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SNTI
• Website: https://www.sentibio.com

Analyst Forecast

According to one analyst, the rating for SNTI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(288.35% upside)

Analyst Consensus: Strong Buy